GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Sale Of Investment

Oculis Holding AG (FRA:CR5) Sale Of Investment : €0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Sale Of Investment?

Oculis Holding AG's sale of investment for the three months ended in Mar. 2024 was €0.00 Mil. It means Oculis Holding AG gained €0.00 Mil from selling investments. Oculis Holding AG's sale of investment for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Dec. 2023 ), Oculis Holding AG gained the same money from selling investments in Mar. 2024 (€0.00 Mil).


Oculis Holding AG Sale Of Investment Historical Data

The historical data trend for Oculis Holding AG's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Sale Of Investment Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Sale Of Investment
- - - -

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Oculis Holding AG Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oculis Holding AG Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Oculis Holding AG (FRA:CR5) Business Description

Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines